GSK3B and Alzheimer disease: An siRNA mediated GSK-3β knockdown model showed a reduction of AD pathology through the restoration of the insulin signaling AMPK and Mapk3 pathways, resulting in improved cellular energy homeostasis, neuronal health, with reduced Aβ and tau formation in the cortex and hippocampus (Gupta et al., 2022).